Systemic therapies for unresectable locoregional melanoma: a significant area of need

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2019-09-02 DOI:10.2217/mmt-2019-0010

E. Nan Tie, J. Lai-Kwon, D. Gyorki

引用次数: 7

Abstract

Immune checkpoint inhibitors and BRAF-MEK inhibitors have revolutionized the management and prognosis of patients with metastatic melanoma. However, there is minimal evidence to guide their incorporation into current treatment paradigms for unresectable stage III disease. The era of effective systemic therapies has prompted a discussion about what constitutes unresectable disease. Patients with unresectable stage III disease can experience significant morbidity from their disease and locoregional therapies, and may progress with distant metastases. Despite increasing use of systemic therapies in unresectable stage III disease, further evidence is needed to establish their degree of benefit in this population.

查看原文本刊更多论文

不可切除的局部黑色素瘤的全身治疗:一个重要的需要领域

免疫检查点抑制剂和BRAF-MEK抑制剂已经彻底改变了转移性黑色素瘤患者的管理和预后。然而，很少有证据指导将其纳入目前不可切除的III期疾病的治疗范例。有效的全身治疗的时代已经引发了关于什么是不可切除疾病的讨论。不可切除的III期疾病患者可经历其疾病和局部治疗的显著发病率，并可能进展为远处转移。尽管在不可切除的III期疾病中越来越多地使用全身疗法，但需要进一步的证据来确定它们在这一人群中的获益程度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.